Status:
UNKNOWN
Evaluation and Validation of Management Strategy for Conductive Disorders After TAVR (EVATAVI)
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Valvular Heart Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Considering decrease of major complications and improvement of procedural results, conductive disorders currently remain the main issue after TAVR (Transcatheter aortic valve replacement). While pace...
Detailed Description
TAVR is now the reference method for the treatment of severe aortic stenosis in the elderly population. Regarding its good results, indications have recently been extended to younger, lower-risk patie...
Eligibility Criteria
Inclusion
- Any patient who benefits from femoral TAVR regardless of the type of valve.
- Age ≥ 18 years old.
Exclusion
- Patients who require CICU monitoring for a reason other than conduction disorders
- Patients with pacemaker or defibrillator
- Pregnant or breastfeeding women
- Patient refusing or unable to give consent: patient under guardianship or curator, mentally retarded, dementia, language barrier
- Patient not affiliated with an SS scheme
- Patient under judicial protection
Key Trial Info
Start Date :
February 21 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 21 2024
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05417464
Start Date
February 21 2023
End Date
March 21 2024
Last Update
March 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Montpellier, France, 34295